Tag: Delandistrogene moxeparvovec

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to Delandistrogene moxeparvovec

Gene Therapy GNT0004 Demonstrates Early Efficacy, Safety in Duchenne Muscular Dystrophy

Added to Collection on: 2024-06-12 22:08:07

Tags for this article:

Muscular dystrophy
Biotechnology
Rare diseases
Genetic engineering
Duchenne muscular dystrophy
Delandistrogene moxeparvovec
Dystrophin-associated protein complex
Sarepta Therapeutics
Gene therapy
Dystrophin
Exon skipping
Steve Wilton
Duchenne

Click the tags to see associated articles and topics

View Article Details
Sarepta Therapeutics Stock Soars on FDA Approval - sharewise

Added to Collection on: 2024-06-21 23:36:18

Tags for this article:

Muscular dystrophy
Biotechnology
Corvallis, Oregon
Sarepta Therapeutics
Delandistrogene moxeparvovec
Duchenne muscular dystrophy
Gene therapy
Dystrophin
DMD
Ezutromid
Steve Wilton

Click the tags to see associated articles and topics

View Article Details
FDA: First gene therapy for rare form of muscular dystrophy

Added to Collection on: 2024-06-22 15:30:32

Tags for this article:

Muscular dystrophy
Biotechnology
Rare diseases
Duchenne muscular dystrophy
Genetic engineering
Sarepta Therapeutics
Delandistrogene moxeparvovec
Gene therapy
Muscular Dystrophy Association
Dystrophin
Dystrophy
Biostrophin
u.s. food and drug administration

Click the tags to see associated articles and topics

View Article Details
Roche's Ocrevus Subcutaneous Gets European Commission Nod By Benzinga

Added to Collection on: 2024-06-26 17:25:05

Tags for this article:

Biotechnology
Corvallis, Oregon
Sarepta Therapeutics
Delandistrogene moxeparvovec
Duchenne muscular dystrophy
Ocrelizumab
Roche
Gene therapy
Multiple sclerosis
Therapy
Accelerated approval

Click the tags to see associated articles and topics

View Article Details
Roche's Ocrevus Subcutaneous Gets European Commission Nod | Markets Insider

Added to Collection on: 2024-06-26 17:09:16

Tags for this article:

Biotechnology
Corvallis, Oregon
Sarepta Therapeutics
Delandistrogene moxeparvovec
Duchenne muscular dystrophy
Ocrelizumab
Roche
Gene therapy
Multiple sclerosis
Therapy
Accelerated approval

Click the tags to see associated articles and topics

View Article Details
FDA Activity Recap: June 2024 Features Expanded Indication Approval, a CRL, RMAT ...

Added to Collection on: 2024-07-06 17:15:14

Tags for this article:

Food and Drug Administration
Biotechnology
Pharmaceuticals policy
Pharmacy
Regenerative Medicine Advanced Therapy
Applied genetics
Sarepta Therapeutics
Gene therapy
Duchenne muscular dystrophy
Delandistrogene moxeparvovec
Priority review
Therapy

Click the tags to see associated articles and topics

View Article Details
Boy with Duchenne's Gets Gene Therapy 3 Days Before He's Ineligible (Exclusive)

Added to Collection on: 2024-10-05 14:21:00

Tags for this article:

Muscular dystrophy
Duchenne muscular dystrophy
Muscular Dystrophy Association
Delandistrogene moxeparvovec
Dystrophin
Dystrophy
Biostrophin
Limb–girdle muscular dystrophy
Hudson Sanford
Melanie Sanford Sanford
Melanie Sanford

Click the tags to see associated articles and topics

View Article Details
Consumer groups ask FTC to block Novo Holdings-Catalent deal | The Mighty 790 KFGO

Added to Collection on: 2024-10-17 18:43:22

Tags for this article:

Peptide hormones
Biotechnology
PEPTIDE THERAPEUTICS
Catalent
Gene therapy
Research and development in the United States
Novo Nordisk
GLP-1 receptor agonist
Semaglutide
Sarepta Therapeutics
Delandistrogene moxeparvovec
Glucagon-like peptide-1

Click the tags to see associated articles and topics

View Article Details
Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent ...

Added to Collection on: 2024-11-06 22:03:35

Tags for this article:

Biotechnology
Corvallis, Oregon
Sarepta Therapeutics
Delandistrogene moxeparvovec
Duchenne muscular dystrophy
Gene therapy
Muscular dystrophy
Duchenne
Magnetic resonance imaging
Sarepta Therapeutics Inc.

Click the tags to see associated articles and topics

View Article Details
Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy

Added to Collection on: 2024-11-19 17:37:27

Tags for this article:

Muscular dystrophy
Biotechnology
Rare diseases
Corvallis, Oregon
Sarepta Therapeutics
Duchenne muscular dystrophy
Delandistrogene moxeparvovec
Gene therapy
Dystrophin
REGENXBIO

Click the tags to see associated articles and topics

View Article Details